Market Overview

UPDATE: Stifel Downgrades Theravance Following Post-Split Accretion

Related THRX
Glaxosmithkline, Theravance Intend to File Relvar Ellipta for COPD in Japan
Theravance Just Lost Its Catalyst
After Hours Gainers / Losers (Seeking Alpha)

In a report published Thursday, Stifel analyst Stephen Willey downgraded the rating on Theravance (NASDAQ: THRX) from Buy to Hold, and removed the $47.00 price target.

In the report, Stifel noted, “We are viewing the recent post-split accretion in THRX shares as an opportunity to step to the sidelines. We believe the justification of additional upside from here requires a significant acceleration of Breo sales not supported by current script trends and likely further confounded by the longer-term cannibalization of sales following the introduction of triple-therapy.

"Our reduced peak Breo sales estimate ($2.1B vs. prior $2.7B) remains heavily-dependent on a FY15 U.S. asthma label. Our longer-term enthusiasm for Anoro in COPD remains unchanged ($2.1B peak), but the initial Breo-like launch trajectory further exacerbates the lack of urgency here. Fair value is now estimated at approximately $25/share.”

Theravance closed on Wednesday at $26.40.

Latest Ratings for THRX

May 2015Cowen & CompanyDowngradesMarket Perform
Jul 2014Bank of AmericaDowngradesBuyNeutral
Jun 2014Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for THRX
View the Latest Analyst Ratings

Posted-In: Stephen Willey StifelAnalyst Color Downgrades Analyst Ratings


Related Articles (THRX)

Get Benzinga's Newsletters